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Persistent high-risk (HR) human papillomavirus (HPV) infection is necessary for development of precursor lesions and cervical
cancer. We investigate persistence and clearance of HPV infections and cofactors in unvaccinated women. Cervical samples of 569
women (18–75 years), received for routine evaluation in the Health Department of Ouro Preto, Brazil, were collected and subjected
to PCR (MY09/11 or GP5+/6+ primers), followed by RFLP or sequencing. All womenwere interviewed to collect sociodemographic
and behavioral information. Viral infection persistence or clearance was reevaluated after 24 months and was observed in 59.6%
and 40.4% of women, respectively. HPVs 16, 33, 59, 66, 69, and 83 (HR) were the most persistent types whereas HPVs 31, 45, and 58
were less persistent. Clearance or persistence did not differ between groups infected by HPVs 18, 53, and 67. In low-risk (LR) types,
HPV 6 infected samples were associated with clearance, while HPV 11, 61, 72, or 81 infected samples were persistent in the follow-
up. No statistically significant association was detected between persistent HPV infections and sociodemographic and behavioral
characteristics analyzed. To study persistence or clearance in HPV infection allows the identification of risk groups, cofactors, and
strategies for prevention of cervical cancer.
1. Introduction
Human papillomavirus (HPV) infections are the most com-
monly diagnosed sexually transmitted disease. More than
100HPV types have been identified. They infect the skin
squamous epithelia and mucosa and usually cause benign
papillomas or warts. Persistent infection with oncogenic
high-risk HPV causes all cervical cancers, most anal cancers,
and a subset of vulvar, vaginal, penile, and oropharyngeal
cancers [1–3].
The major steps in cervical carcinogenesis include HPV
infection, HPV persistence for a certain period of time,
progression to precancer, and invasion [4, 5].
HPV infection alone may not be sufficient to cause
cervical cancer, and other factors influence the risk of pro-
gression to cervical cancer. High parity, smoking, long-term
use of oral contraceptives, sexual behavior, genetic factors,
and coinfection with other sexually transmitted infectious
agents such as herpes simplex virus 2 (HSV-2) andChlamydia
trachomatis have been established as cofactors for cervical
cancer among women with persistent infections [6–9].
Although these environmental and genetic factors are
considered to act as HPV cofactors contributing to progres-
sion from viral infection to cervical cancer, few prospective
studies have addressed the roles that these risk factors play
in the natural history of precursor lesions. The knowledge of
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epidemiology and natural history of HPV infection (acqui-
sition, clearance, and persistence) is relevant and can direct
interventions to prevent preneoplastic lesions and cervical
cancer [4].
There is evidence that most HPV infections are transient
and clear spontaneously within 12–24 months after first
detection. Persistent HPV infection with elevated risk of
cervical cancer occurs in only a small percentage of virus
infected women [5, 10]. The reasons of this fact are still
unknown.
The importance of HPV clearance/persistence has been
recognized recently, and the number of studies addressing
these issues has increased substantially during the past
few years. However, data are still incomplete and in part
inconsistent as to the cofactors that regulate these events
[11, 12].
In Ouro Preto, MG, Brazil, a recent study showed preva-
lence of HPV infections in women with normal cervical
cytology. Different subtypes of high-risk HPV (mainly HPV
16) were predominant. Furthermore, age, literacy, residence,
marital status, smoking status, and number of sexual partners
were independently associated with HPV infection [13].
HPV-positive women in this prevalence study have been
accompanied to assess the natural history of viral infection.
Therefore, the aim of this study was to investigate persistence
and clearance of HPV infections in unvaccinated women and
cofactors correlated with such events.
2. Material and Methods
Ethical Statements. The protocols used in this study were
approved by the Ethical Committee in Research of the Uni-
versidade Federal de Sa˜o Paulo (number 0832.08) assigned by
the president of this committee.
The sample was composed of 569 women (aged 18 to
75 years) living in Ouro Preto, MG, Brazil. Women were
randomly selected when they visited health units for routine
gynecological evaluation and they were not enrolled in
the study if they were pregnant, diagnosed with mental
incompetence, or diagnosed with carcinoma, except the
cervical cancer. This project was reviewed and approved by
the Institutional Ethic Committee, and informed consent was
obtained from private interviews at the time of gynecological
evaluation.
Sociodemographic characteristics, smoking status, alco-
hol consumption, bracken fern diet, and sexual and reproduc-
tive behavior were obtained from private interviews with the
women at the time of the gynecological evaluation. Subjects
were considered as nonsmokers or nonalcohol consumers
if they have never smoked or drunk. Speculum exami-
nation was performed by gynecologists; cervical samples
were obtained using an extended tip “Ayre” spatula. The
conventional cervical smear was spread onto a glass slide and
the tip of the spatula was broken off and placed in a container
containing preservation solution for HPV testing.
2.1. HPV-DNA Typing. For the extraction of DNA from
cervical samples, we used a GenomicPrep Blood kit (GE
Healthcare), with proteinase K digestion. HPV was detected
by the amplification of DNA by using a standard polymerase
chain reaction (PCR) protocol with L1 consensus primer
pair MY09 and MY11, which promotes amplification of an
approximately 450 bp product and can detect more than 40
distinct low- and high-risk genital HPV types. Positive and
negative controls were used in all tests.The amplification was
performed according to the following protocol: 94∘C for 30 s,
51.5∘C for 30 s, and 72∘C for 30 s for 35 cycles, followed by a
final step at 72∘C for 7min [14, 15]. The 𝛽-actin gene primers
were used as internal controls.
We used RT-PCR with primers GP5+/6+ for HPV detec-
tion in samples with no conclusive diagnosis using primers
MY09/11. The reactions were performed using SYBR Green
PCRMasterMix (Applied Biosystems) and conducted in ABI
7000 Applied Biosystems.
HPV-DNA-positive specimens were typed by restric-
tion fragment length polymorphism (RFLP), according to
Bernard et al. 1994 [16]. Samples with positive HPV viral
types not identified by RFLP were identified by sequencing
of the PCR product using BigDye Terminator kit (Applied
Biosystems). Sequences were generated on ABI model 377
automated sequencer (Applied Biosystems) and aligned to
HPV sequences at Genbank using BioEdit Sequence Align-
ment Editor 7.0.9.0.
2.2. Follow-Up Study. HPV infection was detected in 133
women, who were invited to participate in a follow-up study,
consisting of a second cervical scrape specimen collection
24 months from first recruitment, using the same procedure
as the initial examination. 89 women (66.9%) completed the
survey and were tested for HPV in 24 months. 44 women
(33.1%) were lost in the follow-up.
After 24 months (second cervical scrape specimen for
cytology and HPV testing), all women were interviewed
again, with the same questionnaire used in first collection,
and the information was updated.
Persistent type-specific HPV infection was defined as the
detection of the same HR-HPV type at both examinations
(first study and follow-up study). Clearancewas defined as the
proportion of women who were initially HR-HPV positive
(first collection), but the same HR-HPV type was not found
at the follow-up [12].
2.3. Statistical Analysis. Descriptive statistics were used for
the analysis of persistence and clearance of type-specificHPV
infection. Particularly, Pearson’s 𝑥2 test was used to verify
the association between all independent variables and the
response variable. 𝑃 < 0.05 was considered statistically
significant. Statistical analyses were performed using SPSS
software for Windows (version 18.0).
3. Results and Discussion
3.1. Results
3.1.1. Profile of the Initial Sample. Analyses of this study were
performed with samples of 89 women, mean age of 37.7
(±12.6) years.
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Table 1: Evolution of HPV infection related to virus oncogenic risk
and type of infection.
Total
𝑁
Clearance
𝑛 (%)
Persistence
𝑛 (%) 𝑃
Infection
Single 80 34 (42.5) 46 (57.5) 0.210
Multiple 9 2 (22.2) 7 (77.8)
Oncogenic risk
LR-HPV 17 5 (29.4) 12 (70.6)
0.082IR-HPV 17 10 (58.8) 7 (41.2)
HR-HPV 55 21 (38.2) 34 (61.8)
These samples were composed predominantly of women
with the following characteristics: age ≥30 years (68.5%);
resident in urban areas (76.4%); only one sexual partner in
lifetime (51.7%); no use of oral contraceptives (52.8%); alcohol
consumption (61.8%); 1–5 pregnancies (66.3%); bracken fern
consumption in usual diet (68.5%); smoking (40.4%). Only
20.2%ofwomen in the grouphad early onset of sexual activity
(≤15 years).
Simple infections, by a single viral type, were predomi-
nant (80 women, 89.9%) and multiple HPV infections were
detected in 10.1%.
High-risk (HR) HPV types (mainly HPV16) were more
prevalent in the study samples. HR-HPV was detected in 55
(61.8%) women, indeterminate risk (IR) HPV in 17 (19.1%)
and low risk (LR) in 17 (19.1%) women.
3.1.2. Evaluation after 24-Month Follow-Up. Among the 89
women HPV positive at baseline, 53 (59.6%) had persistent
infection and 36 (40.4%) had clearance of the infection after
24 months.
Table 1 shows clearance or persistence of viral infection in
relation to number and risk of HPV types.
Most women with multiple infections (77.8%) showed
persistence after 24 months of follow-up. However, presence
of multiple infections was not statistically associated with
persistent HPV infection (Table 1).
Similarly, in relation to risk oncogenic HPV types, no
statistical difference was observed between persistence of
viral infection and HR-HPV types. The infection persisted
after follow-up in 61.8% of samples infected by HR-HPV and
in 70.6% by LR-HPV (Table 1).
Among specific HR-HPV types, HPV 16, 33, 59, 66, 69,
and 83 were the most persistent types whereas HPVs 31, 45,
and 58 were the less persistent. Clearance or persistence did
not differ between groups infected by HPVs 18, 53, and 67
(Table 2).
Regarding specific LR-HPV types, HPV 6 infected sam-
ples were associated with clearance. In contrast, HPV 11, 61,
72, or 81 infected samples were associated with persistent
infections in the 24-month follow-up (Table 3).
Table 4 shows that no statistically significant association
was detected between persistentHPV infections and sociode-
mographic and behavioral characteristics evaluated.
Table 2: Persistence or clearance of specific high-risk (HR) HPV
infection after follow-up.
HPV types Clearance
𝑛 (%)
Persistence
𝑛 (%)
Total
𝑁
16 12 (35.3) 22 (64.7) 34
18 3 (50) 3 (50) 6
31 2 (100) 0 (0) 2
33 0 (0) 2 (100) 2
45 1 (100) 0 (0) 1
53 1 (50) 1 (50) 2
58 1 (100) 0 (0) 1
59 0 (0) 1 (100) 1
66 0 (0) 1 (100) 1
67 1 (50) 1 (50) 2
69 0 (0) 1 (100) 1
83 0 (0) 2 (100) 2
HR-HPV 21 (38.2) 34 (61.8) 55
Table 3: Persistence or clearance of specific low-risk (LR) HPV
infection after follow-up.
HPV types Clearance
𝑛 (%)
Persistence
𝑛 (%)
Total
𝑁
6 4 (66.7) 2 (33.3) 6
11 0 (0) 2 (100) 2
61 1 (14.3) 6 (85.7) 7
72 0 (0) 1 (100) 1
81 0 (0) 1 (100) 1
LR-HPV 5 (29.4) 12 (70.6) 17
4. Discussion
We have analyzed the prevalence of HPV infection in women
presenting normal cervical cytology [13] and in women living
in rural and urban areas of Ouro Preto,MG, Brazil [17]. HPV-
positive women were followed for 24 months. In general,
persistence of HPV infection was 59.6% and clearance was
40.4%. It is believed thatHPV infections “clear”within 2 years
in more than 90% of individuals [5, 18–20]. Therefore, the
percentage of HPV clearance was low in our study but similar
results were also obtained by Banura et al., 2010 [21], and Guo
et al., 2010 [22].
Considering only HR-HPV infections, the persistence
was 61.8% and clearance was 38.2%. This result was similar
to that reported in studies in Brazil [23] and other countries
[12, 24, 25].
However, unlike what is expected we observed high
persistence (70.6%) and low clearance (29.4%) of LR-HPV
infections, proportions similar to those obtained for HR-
HPV types. This may be due to the small number of women
with each viral type or time of follow-up. Banura et al., 2010
[21], showed clearance LR-HPV ranged between 50% and
100%. Other studies also observed that clearance proportion
was similar in HR-HPV and LR-HPV [21, 26]. We found
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Table 4: Evolution of HPV infection related to sociodemographic
and behavioral characteristics.
Total
𝑁
Clearance
𝑛 (%)
Persistence
𝑛 (%) 𝑃
Age groups (years)
>30 28 11 (39.3) 17 (60.7)
0.65730 to 39 20 7 (35.0) 13 (65.0)
40 to 49 25 11 (44.0) 14 (56.0)
>50 16 7 (40.4) 9 (56.3)
Residence
Rural 21 10 (47.6) 11 (52.4) 0.303
Urban 68 26 (38.2) 42 (61.8)
Age at first intercourse
(years)
≤15 18 8 (44.4) 10 (56.6) 0.449
>15 71 28 (39.4) 43 (60.6)
Number of lifetime
sexual partners
1 46 18 (39.1) 28 (60.9)
0.0512 to 4 28 8 (28.6) 20 (71.4)
5 or more 15 10 (66.7) 5 (33.3)
Oral contraceptive use
No 47 19 (40.4) 28 (59.6) 0.583
Yes 42 17 (40.5) 25 (59.5)
Parity
0 19 8 (42.1) 11 (57.9)
0.5091 to 5 59 25 (42.4) 34 (57.6)
6 or more 11 3 (27.3) 8 (72.7)
Bracken fern
consumption
No 28 12 (42.9) 16 (57.1) 0.466
Yes 61 24 (39.3) 37 (60.7)
Smoking
No 53 19 (35.8) 34 (64.2) 0.197
Yes 36 17 (47.2) 19 (52.8)
Alcohol consumption
No 34 13 (38.2) 21 (61.8) 0.457
Yes 55 23 (41.8) 32 (58.2)
that HPV 16, 33, 59, 66, 69, and 83 infections were the
most persistent. Studies have reported that HPV 16 was
significantly more likely to persist than were all other viral
types [21, 25, 27]. Moreover, Sammarco et al., 2013 [12],
observed that HPV types with the highest likelihood of
persistence were 31, 39, and 73, whilst HPV 16 was the
least persistent. Persistent infections have a higher risk of
progression to precursor lesions and cervical cancer.
In this study, most of women with multiple infections
showed persistence after 24 months of follow-up. Similar
results were obtained by Trottier et al., 2008 [28], Nielsen et
al., 2010 [27], Castle et al., 2011 [29], and Schmeink et al., 2013
[26], who reported that infection with multiple HPV types
is associated with longer persistence of HPV infection. This
association was not observed by Sammarco et al., 2013 [12].
In the literature, associations of HPV persistence or
clearance with cofactors vary widely due to the sample size,
population characteristics, and study design. In this study,
therewas no significant association betweenHPVpersistence
or clearance and the analyzed cofactors. Schmeink et al., 2013
[26], suggest that HPV clearance is mainly related to the host
immune response or other intrinsic host factors and not to
present behavior factors.
There are reports that women with persistent HR-HPV
infections were younger than those who cleared their infec-
tions [12, 30, 31]. Others showed that persistence increased
with age [29]. However, no association between HPV persis-
tence and age was found in this study as in Trottier et al., 2008
[28], and Muoz et al., 2009 [32].
Likewise in this work, some studies found no association
between persistent HPV infection and smoking, number of
sexual partners, oral contraceptive use, and high parity [12,
26, 27, 30, 33].
Persistent high-risk HPV infection also was associated
with high viral load [22, 34].
The main limitations of this study were sample size
and follow-up period. This prevented extensive discussion
of some results and direct comparison with other studies.
Furthermore, it is important to emphasize that our data were
based solely on the detection of DNA in cervical samples.
HR-HPV persistence plays a key role in the progression
of preneoplastic lesions and in the development of cervical
cancer. Thus, epidemiological and biological understanding
of the natural history of HPV infection is critical to guide
the implementation of strategies for prevention and control
of cervical cancer.
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